Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
Jan K Buitelaar1, J Antoni Ramos-Quiroga2, Miguel Casas2, J J Sandra Kooij3, Asko Niemelä4, Eric Konofal5, Joachim Dejonckheere6, Bradford H Challis7, Rossella Medori81Department of Psychiatry, University Medical Center, St. Radboud and Karakter Child and Adolescent Psychiatry Universit...
Guardado en:
Autores principales: | Jan K Buitelaar, J Antoni Ramos-Quiroga, Miguel Casas, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4949a218c0e4438cbed2e44a68f7c832 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Social adjustment and family function after drug switch from IR -methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder
por: Chou WJ, et al.
Publicado: (2018) -
Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride
por: Rajasree Nair, et al.
Publicado: (2009) -
Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study
por: Valdizán-Usón JR, et al.
Publicado: (2013) -
Effects of melatonin in children with attention-deficit/hyperactivity disorder with sleep disorders after methylphenidate treatment
por: Masi G, et al.
Publicado: (2019) -
Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment
por: Huss M, et al.
Publicado: (2016)